Ucb Stock

Ucb EBIT

The EBIT of Ucb (UCB.BR) as of Aug 14, 2026 is 1.17 B EUR. In the previous year, EBIT was 1.32 B EUR — a change of -11.93% (lower).

EBIT

1.17 BEUR

YoY

-11.93%

Last updated:

In 2026, Ucb's EBIT was 1.17 B EUR, a -11.93% increase from the 1.32 B EUR EBIT recorded in the previous year.

The Ucb EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (B EUR)
Date
EBIT (B EUR)
Jan 1, 2023
0.60 base
Jan 1, 2024
1.32 base
Jan 1, 2025
1.17 base
Jan 1, 2026 (e)
1.37 base
Jan 1, 2027 (e)
1.55 base
Jan 1, 2028 (e)
1.74 base
Jan 1, 2029 (e)
1.92 base
Jan 1, 2030 (e)
2.06 base
YEAREBIT (B EUR)
2030 est 2.06
2029 est 1.92
2028 est 1.74
2027 est 1.55
2026 est 1.37
2025 1.17
2024 1.32
2023 0.60
2022 0.58
2021 1.27
2020 0.98
2019 1.02
2018 1.11
2017 1.03
2016 0.80
2015 0.58
2014 0.38
2013 0.31
2012 0.39
2011 0.34
2010 0.20
2009 0.84
2008 0.11
2007 0.34
2006 0.57
Access this data via the Eulerpool API

Ucb Revenue

Ucb Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
5.25 B EUR
604.00 M EUR
343.00 M EUR
Jan 1, 2024
6.15 B EUR
1.32 B EUR
1.07 B EUR
Jan 1, 2025
7.74 B EUR
1.17 B EUR
1.56 B EUR
Jan 1, 2026 (e)
8.54 B EUR
1.37 B EUR
2.12 B EUR
Jan 1, 2027 (e)
9.63 B EUR
1.55 B EUR
2.65 B EUR
Jan 1, 2028 (e)
10.84 B EUR
1.74 B EUR
3.31 B EUR
Jan 1, 2029 (e)
11.99 B EUR
1.92 B EUR
4.04 B EUR
Jan 1, 2030 (e)
12.86 B EUR
2.06 B EUR
4.64 B EUR

Ucb Margins

Ucb stock margins

The Ucb margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ucb. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ucb.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
67.50 %
11.50 %
6.53 %
Jan 1, 2024
71.52 %
21.52 %
17.31 %
Jan 1, 2025
71.14 %
15.06 %
20.13 %
Jan 1, 2026 (e)
71.14 %
16.09 %
24.77 %
Jan 1, 2027 (e)
71.14 %
16.14 %
27.52 %
Jan 1, 2028 (e)
71.14 %
16.05 %
30.50 %
Jan 1, 2029 (e)
71.14 %
16.05 %
33.71 %
Jan 1, 2030 (e)
71.14 %
16.05 %
36.06 %

Ucb Stock analysis

What does Ucb do? The company UCB SA is a Belgian pharmaceutical company that was founded in 1928 and is now active worldwide. The business model of UCB SA is based on the discovery and development of medications for severe diseases. The core competencies of the company are in neurology, immunology, and cardiology. In the history of UCB SA, there are several milestones. In 1961, UCB SA succeeded in synthesizing antihistamines, which marked the beginning of the development of medications for allergic diseases. In the 1990s, UCB SA began to focus on the development of medications for the treatment of epilepsy and Parkinson's disease. In the 2000s, UCB SA acquired several companies, expanding its portfolio of medications and its geographic reach. The company operates three different divisions: pharmaceuticals, biopharmaceuticals, and specialty chemicals. In the pharmaceuticals division, UCB SA develops and distributes medications for the treatment of epilepsy, Parkinson's disease, and autoimmune diseases such as rheumatoid arthritis and lupus. UCB SA's biopharmaceutical division focuses on researching antibodies for the treatment of various diseases such as cancer and multiple sclerosis. In the specialty chemicals division, UCB SA produces chemical products such as solvents and paints. The company offers a wide range of products tailored to the needs of patients with various diseases. One example of a well-known product from UCB SA is Keppra, a medication for the treatment of epilepsy. Keppra is one of the most prescribed medications for epilepsy and has helped improve the lives of millions of patients. Another example is Cimzia, a medication for the treatment of rheumatoid arthritis, Crohn's disease, and ulcerative colitis. Cimzia belongs to a new generation of medications that aim to selectively influence the immune system and thus inhibit inflammation. UCB SA places great value on innovation and constantly researches new medications and therapies. The company has a strong research and development team with over 3,000 employees and invests approximately 25% of its revenue annually in the research and development of new medications. Overall, UCB SA is an innovative and successful pharmaceutical company with a broad portfolio of medications and a strong commitment to the quality of the products developed. The company is dedicated to improving the lives of patients with severe diseases and remains a key player in the global pharmaceutical industry in the long term. Ucb is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Ucb's EBIT

Ucb's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Ucb's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Ucb's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Ucb’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Ucb stock

EBIT of Ucb is 1.17 B EUR in 2026.

EBIT of Ucb changed from 1.32 B EUR to 1.17 B EUR, representing a -11.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Ucb since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Ucb historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Ucb

All Key Metrics — Ucb